| Serial Number | 97975242 |
| Word Mark | ALLISON INSTITUTE |
| Filing Date | Friday, March 25, 2022 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Thursday, April 11, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 21, 2023 |
| Goods and Services | Charitable fundraising services |
| Goods and Services | Promoting collaboration within the scientific, research, pharmaceutical, and medical communities to achieve advances in healthcare, including to accelerate the development and use of immunotherapy in treatment of disease |
| Goods and Services | Providing patient advocate services in the treatment of diseases and disorders utilizing immunotherapy |
| Goods and Services | Medical services; Dispensing of pharmaceuticals; Medical and pharmaceutical consultation; Medical services relating to cancer; Dispensing of pharmaceuticals relating to cancer; immunobiology and immunotherapy medical services; medical services, namely, the treatment of cancer, disease management, disease prevention and early detection, standardized diagnosis, staging and treatment, care and care assessment, medical counseling; medical consulting services, namely, consulting on the treatment of cancer, disease management, disease prevention and early detection, standardized diagnosis, staging and treatment, care and care assessment, and patient care management; providing medical information; providing health information in the field of immunobiology, immunotherapy, oncology and diseases; providing a web site featuring medical information; providing a web site featuring health information in the field of immunobiology, immunotherapy, oncology and diseases; providing medical information, consultancy and advisory services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, medical diagnostic testing, monitoring and reporting services; providing information on health care via a telephone and the internet; providing information on cancer treatment; medical services, namely, treatment in the field of oncology and related health problems and diseases; providing medical information to patients and medical professionals in the field of immunotherapy and cancer treatment; medical analysis services, namely, analysis of tumors, cancer or equivalent medical conditions |
| Disclaimer with Predetermined Text | "INSTITUTE" |
| Goods and Services | Medical research services; medical research, development, technical design, testing, and analysis services in the field of immunobiology, immunotherapy, antibodies, and oncology; consulting services in the field of immunobiology, immunotherapy, antibodies, and oncology; medical research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; medical research services in the field of immune repertoire analysis and the genome; scientific research in the fields of immunobiology, immunotherapy, antibodies and oncology; biological research; laboratory research services in the fields of immunobiology, immunotherapy, antibodies, oncology, and cellular engineering; medical laboratory services; providing information on medical and scientific research in the field of immunobiology and immunotherapy; medical and scientific research for others in the field of stem cell research, cancer, immunobiology and immunotherapy; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research liaison services, namely, consulting in the field of scientific research pertaining to clinical trials in the fields of health care, medicine, immunobiology, immunotherapy, pharmacology and biotechnology; collection and management of medical and scientific data for research purposes in the field of medical and scientific research; Pharmaceutical research services; Pharmaceutical research services relating to cancer |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 11, 2023 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 036 - Insurance; financial affairs; monetary affairs; real estate affairs. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, March 30, 2022 |
| Primary Code | 036 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 11, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 11, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, March 30, 2022 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | The Board of Regents of the University of Texas System |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 14 - State Agency |
| Address | Austin, TX 78701 |
| Party Name | The Board of Regents of the University of Texas System |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 14 - State Agency |
| Address | Austin, TX 78701 |
| Event Date | Event Description |
| Friday, April 12, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, April 11, 2024 | SOU EXTENSION 2 GRANTED |
| Thursday, April 11, 2024 | SOU EXTENSION 2 FILED |
| Thursday, April 11, 2024 | SOU TEAS EXTENSION RECEIVED |
| Friday, October 13, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, October 11, 2023 | SOU EXTENSION 1 GRANTED |
| Wednesday, October 11, 2023 | SOU EXTENSION 1 FILED |
| Wednesday, October 11, 2023 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, April 18, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, February 21, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 21, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, February 1, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 17, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, January 11, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, January 11, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, January 11, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, January 11, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, December 12, 2022 | DIVISIONAL PROCESSING COMPLETE |
| Tuesday, November 1, 2022 | DIVISIONAL REQUEST RECEIVED |
| Monday, December 5, 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, November 1, 2022 | TEAS REQUEST TO DIVIDE RECEIVED |
| Monday, August 29, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, August 29, 2022 | NON-FINAL ACTION E-MAILED |
| Monday, August 29, 2022 | NON-FINAL ACTION WRITTEN |
| Thursday, August 25, 2022 | ASSIGNED TO EXAMINER |
| Wednesday, March 30, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, March 29, 2022 | NEW APPLICATION ENTERED |